Welcome to our dedicated page for Qsam Biosciences news (Ticker: QSAM), a resource for investors and traders seeking the latest updates and insights on Qsam Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Qsam Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Qsam Biosciences's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
QSAM Biosciences Inc. (OTCQB: QSAM), based in Austin, TX, announced an important milestone on April 26, 2023. The European Patent Office (EPO) has allowed a patent protecting the use of lower specific activity Samarium-153 for treating bone cancer in both children and adults. This patent covers high purity therapeutic agents licensed to QSAM and introduces a novel production method that reduces impurities, potentially enabling higher and multiple dosing regimens for various metastatic bone cancers.
The CEO, Douglas R. Baum, emphasized the significance of repeated dosing regimens in treating bone tumors and the company’s ongoing clinical trials. This patent marks the second in Europe and is expected to enhance QSAM’s patent estate, expanding its commercial market potential for breakthrough therapies in bone cancer treatment.
QSAM Biosciences Inc. (OTCQB: QSAM) has commenced enrollment for the second cohort in its Phase 1 study of CycloSam® for metastatic bone cancer treatment. Following positive safety data from the first cohort, the company is increasing the dosage by 50% for new participants. With nearly $3 million raised in a recent private placement and the conversion of outstanding convertible notes, QSAM is positioned to advance its clinical trials. CycloSam® targets bone cancer types that frequently have poor outcomes, as evidenced by approximately 400,000 new cases of malignant bone metastasis annually in the U.S. QSAM aims to address this significant medical need.
QSAM Biosciences (OTCQB: QSAM) is set to present updates on its clinical trial for CycloSam®, a next-generation therapeutic radiopharmaceutical targeting metastatic bone cancer, at the Emerging Growth Conference on March 22, 2023. The presentation will occur at 2:50 PM EST and will last approximately 10 minutes, allowing investors and analysts to engage with the company's executive team. CycloSam® has shown preliminary safety and efficacy in prior studies, and QSAM is optimistic about its commercialization path given its innovative technology. Interested parties can register online to attend.
FAQ
What is the current stock price of Qsam Biosciences (QSAM)?
